Brain Tumor Treatment Market, By Treatment Modality (Chemotherapy (e.g., alkylating agents, cytotoxic drugs), Radiation Therapy (e.g., external beam radiation, stereotactic radiosurgery), Targeted Therapy (e.g., molecularly targeted small molecules), Immunotherapy (e.g., checkpoint inhibitors, CAR T therapies), and Other Therapies (e.g., tumor treating fields, gene therapy, combination modalities)), By Tumor Type (Primary Brain Tumors (e.g., glioblastoma, astrocytoma), Metastatic/Secondary Brain Tumors, Meningioma, Pituitary Tumors, and Other Tumor Types (e.g., oligodendroglioma, ependymoma)), By Drug Class (Alkylating Agents, Antimetabolites , Monoclonal Antibodies, Small Molecule Inhibitors, and Other Drug Classes (e.g., proteasome inhibitors, epigenetic modulators)), By Age Group (Pediatric, Adult, and Geriatric), By Gender (Male and Female), By End User (Hospitals and Integrated Cancer Centers, Ambulatory Surgical/Outpatient Centers, Specialty Clinics (neuro oncology clinics), and Home Care/Remote Care Settings (where applicable)), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By Geography (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa)